<DOC>
	<DOCNO>NCT00658736</DOCNO>
	<brief_summary>This triple-blind , parallel group , randomize control trial ass benefit triamcinolone injection therapeutic measure control chronic pancreatitis pain . The treatment group undergo EUS-CPB bupivicaine plus triamcinolone ( `` therapeutic block '' ) . There control group undergo EUS-CPB bupivicaine alone ( `` diagnostic block '' ) .</brief_summary>
	<brief_title>Efficacy EUS-guided Celiac Plexus Blockade Chronic Pancreatitis</brief_title>
	<detailed_description>There effective option treatment abdominal pain chronic pancreatitis . For past 20 year , percutaneous injection anesthetic agent celiac plexus ( celiac plexus blockade CPB ) perform pain anesthesiologist diagnose origin pancreatic pain ( visceral vs. non-visceral ) . Anesthetic block provide short-term variable pain relief . More recently , endoscopic ultrasound use provide transgastric approach celiac plexus ( EUS-CPB ) . Corticosteroids may lengthen effect CPB provide longer-lasting pain relief ( `` therapeutic block '' ) . Case-series report 50 % patient experience partial complete relief lasting average 1-2 month . Combined corticosteroid ( triamcinolone ) anesthetic ( bupivicaine ) become standard practice EUS-CPB . However , randomize control trial prove corticosteroid block truly therapeutic ( i.e . lengthen effect typical `` diagnostic '' CPB anesthetic ) . Randomized controlled trial need demonstrate therapeutic efficacy CPB corticosteroid . This triple-blind , parallel group , randomize control trial ass benefit triamcinolone injection therapeutic measure control chronic pancreatitis pain . The treatment group undergo EUS-CPB bupivicaine plus triamcinolone ( `` therapeutic block '' ) . There control group undergo EUS-CPB bupivicaine alone ( `` diagnostic block '' ) . Eligible patient abdominal pain undergoing EUS diagnosis chronic pancreatitis EUS-CPB pancreatic pain recruit . Patients complete 2-week run-in period establish baseline pain score opioid consumption . Following run-in , EUS perform . If EUS reveals CP ( &gt; 4 criterion ) , patient randomize one two treatment group . 74 patient randomize follow 2 month EUS-CPB . The primary endpoint improvement pain disability index ( PDI ) great 10 point 1 month . Secondary endpoint include opioid consumption , duration pain relief , quality life ( SF-12 ) . If trial show addition triamcinolone produce long-lasting ( 1-month ) benefit , EUS-CPB strongly advocate therapeutic option patient chronic pancreatitis . If triamcinolone produce benefit diagnostic block , EUS-CPB consider primarily diagnostic measure differentiation visceral non-visceral pain .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Inclusion criterion include : Age &gt; 18 yr Ability inform consent Chronic pancreatictype abdominal pain ( type B ) ( 11 ) . Exclusion criterion include : Pregnancy Malignancy Recent acute pancreatitis ( within 2 month ) Elevated INR ( &gt; 1.5 ) low platelet count ( &lt; 75 cells/mm3 ) Allergy egg `` caine '' anesthetic corticosteroid ; AND Becks depression score &gt; 20 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>